Acumen Pharmaceuticals, Inc.
NASDAQ:ABOS
3.17 (USD) • At close November 7, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Acumen Pharmaceuticals, Inc. |
Symbool | ABOS |
Munteenheid | USD |
Prijs | 3.17 |
Beurswaarde | 190,452,966 |
Dividendpercentage | 0% |
52-weken bereik | 1.81 - 5.09 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Daniel J. O'Connell M.B.A. |
Website | https://acumenpharm.com |
An error occurred while fetching data.
Over Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)